megestrol

P4, N=80, Not yet recruiting, Hospital Universitari de Bellvitge | Trial completion date: Sep 2028 --> Jan 2035 | Initiation date: Sep 2026 --> Jan 2027 | Trial primary completion date: May 2027 --> Apr 2031

P2, N=44, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Feb 2027

The AMPK-FOXO1-CALB2 axis mediates MET-induced mitochondrial dysfunction and apoptosis, providing a mechanistic basis for MET to overcome progesterone resistance in ECC.

One grade 2 thromboembolic event occurred. Despite the small sample size, the observed outcomes support the continued inclusion of MA in ABC guidelines for the treatment of HR+/HER2- MBC, further substantiated by the comprehensive review of clinical evidence and recommendations presented in this article.

P4, N=82, Not yet recruiting, Hospital Universitari de Bellvitge | Phase classification: P --> P4

Fertility-sparing therapy may serve as a potentially feasible option for highly selected patients with stage IA CS-EC, and could lead to relatively favorable pregnancy outcomes. The clinical feasibility of this strategy relies heavily on strict patient selection, timely molecular diagnosis, and standardized continuous multidisciplinary management.

MA significantly improves nutritional status and ameliorates cancer-related fatigue, thereby enhancing the quality of life in patients with cancer cachexia. Our findings provide robust evidence supporting the multi-dimensional benefits of MA in cachexia management, extending beyond mere weight gain to include muscle mass preservation and patient-centered symptom relief.

P2, N=88, Not yet recruiting, Nanfang Hospital, Southern Medical University

Background: Oral progestogens, including megestrol acetate (MA) and medroxyprogesterone acetate (MPA), have largely been superseded by aromatase inhibitors, tamoxifen, and selective oestrogen receptor degraders (SERDs) in oestrogen receptor-positive (ER-positive) metastatic breast cancer. While prior exposure to CDK4/6 inhibitors was associated with shorter PFS, patients without liver metastases appeared to derive the greatest benefit. These findings support a role for oral progestogens in selected patients who have exhausted standard therapeutic options.

P=N/A, N=56, Recruiting, Shandong Cancer Hospital and Institute | Trial completion date: Jul 2027 --> Feb 2028 | Initiation date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jul 2027 --> Dec 2027

This case report describes a 41-year-old patient who, despite PR and PE negativity, responded to conservative management with hysteroscopic resection, a levonorgestrel-releasing intrauterine device, metformin, and later megestrol, achieving complete histological remission in 15 months. The evolving literature suggests that alternative strategies, such as immune modulation and aromatase inhibitors, may further expand options. Individualized management remains crucial, balancing oncological safety with reproductive goals through continuous reassessment and engagement with emerging therapeutic evidence.

P1, N=88, Recruiting, Second Xiangya Hospital of Central South University | Initiation date: Jan 2026 --> Apr 2026